Focusing on patient-centered care, Rana R. McKay, MD, and the Oncology Brothers discuss the role of PSA and PSMA PET scans in guiding treatment for patients with prostate cancer.
The Evolving Landscape of Prostate Cancer Management
Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.
Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC
Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer
Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
Novel PET Imaging Agent Earns Fast Track Status for PSMA+ Prostate Cancer
In 2 clinical trials, 64Cu-SAR-bisPSMA was shown to be effective in detecting prostate cancer in patients with PSMA-positive lesions.